BION 202
Alternative Names: BION-202Latest Information Update: 28 Feb 2023
Price :
$50 *
At a glance
- Originator Biond Biologics
- Class Antibodies; Antineoplastics
- Mechanism of Action Macrophage stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for preclinical development in Cancer in Israel (Parenteral)
- 09 Jan 2019 Preclinical trials in Cancer in Israel (Parenteral) prior to January 2019
- 08 Jan 2019 Biond Biologics plans a phase I trial for Cancer in Israel in 2020 (Biond Biologics pipeline, January 2019)